Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: A prospective cohort study
Yuxin Xie,
Libo Yang,
Yanqi Wu,
Hong Zheng,
Qiheng Gou
Affiliations
Yuxin Xie
Department of Medical Oncology of Cancer Center, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast, West China Hospital, Sichuan University, Chengdu, Sichuan, China
Libo Yang
Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
Yanqi Wu
Department of Medical Oncology of Cancer Center, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast, West China Hospital, Sichuan University, Chengdu, Sichuan, China
Hong Zheng
Department of Medical Oncology of Cancer Center, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast, West China Hospital, Sichuan University, Chengdu, Sichuan, China
Qiheng Gou
Department of Medical Oncology of Cancer Center, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Department of Radiation Oncology and Head & Neck Oncology Division, Cancer Center, West China Hospital, Sichuan University, Chengdu, China; Corresponding author. Department of Medical Oncology of Cancer Center, West China Hospital, Sichuan University, 37 Guoxue Xiang, Wuhou District, Chengdu, 610041, China. Tel: +86-28-85422685
Background: Little is known about the benefits of adjuvant endocrine therapy (ET) in low ER-positive breast cancer (1%–10%) patients. We analyzed the association between ET and breast cancer-specific survival (BCSS) in these patients with respect to the regimen and the duration of ET. Methods: Patients were classified into three groups based on the regimen and duration of ET. The regimens included aromatase inhibitor (AI) monotherapy or sequential tamoxifen followed by an AI (AI/T + AI), or only tamoxifen and no ET. The duration of ET included 2–3 years and >3 years. Multivariate Cox regression analysis was employed to calculate the hazard ratios (HRs) with 95% confidence intervals (CIs). Results: Of the 10,696 patients diagnosed with breast cancer between 2010 and 2020, 407 women were identified with ER-low positive disease and met the inclusion criteria. During a median follow-up of 5.2 years, patients who received ET improved BCSS. Of them, those with AI/T + AI had increased BCSS compared to patients without ET, after adjusting for demographics and tumor characteristics, especially in ER-low/HER-2-positive breast cancer. After additional adjustment for treatment mode, the association maintained a similar trend. Patients who received >3 years of ET was associated with a better DFS. There was no significant difference in BCSS between patients with 2–3 years and >3 years of ET. Conclusion: For ER-low patients, findings suggest that ET with AI/T + AI may be a reasonable treatment alternative. This effect should be assessed in randomized studies.
